AMOXI-CV 625 mg Tablets
Composition: Each tablet contains Amoxicillin 500 mg and Clavulanate Potassium 125 mg.
Product Family: AMOXICV belongs to the penicillin-class antibacterial family combined with a beta-lactamase inhibitor. This combination is designed to provide antibacterial activity against susceptible organisms, including certain bacteria that produce beta-lactamase enzymes.
Product Overview: AMOXICV 625 mg is an established oral antibiotic combination containing amoxicillin and clavulanate. Amoxicillin works by interfering with bacterial cell-wall synthesis, while clavulanate inhibits certain beta-lactamase enzymes that may otherwise reduce amoxicillin activity. Together, these components provide a valuable treatment option for selected susceptible bacterial infections.
Indications: AMOXICV may be prescribed for susceptible bacterial infections, including acute bacterial sinusitis, selected respiratory tract infections, acute otitis media, certain urinary tract infections, and skin and soft-tissue infections. The choice of treatment depends on the suspected or confirmed causative organism, infection severity, local resistance patterns, and applicable clinical guidelines. AMOXICV is not effective against viral infections such as the common cold or influenza.
Clinical Benefits: AMOXICV combines two complementary antibacterial components to help address selected infections caused by susceptible bacteria. The addition of clavulanate can help maintain amoxicillin activity against certain beta-lactamase-producing organisms. Its oral tablet formulation offers a convenient administration option for eligible patients and supports established antibacterial treatment strategies when clinically appropriate.
Mechanism of Action: Amoxicillin inhibits bacterial cell-wall synthesis, leading to the death of susceptible bacteria. Clavulanate inhibits certain beta-lactamase enzymes that can inactivate amoxicillin. This complementary mechanism broadens activity against selected susceptible bacteria compared with amoxicillin alone, although it does not overcome all forms of bacterial resistance.
Dosage and Administration: For adults and patients weighing at least 40 kg, a commonly used regimen for the 500 mg/125 mg formulation is one tablet every 12 hours. The prescribing healthcare professional may select a different regimen when indicated by the approved product information and clinical circumstances. Dosage and treatment duration depend on the type and severity of infection, renal function, patient characteristics, and local guidelines. Patients with renal impairment may require dosage adjustment. Pediatric dosing should be calculated according to body weight and the appropriate pediatric formulation.
Directions for Use: AMOXICV should be taken exactly as prescribed by a qualified healthcare professional. Administration at the beginning of a meal may improve clavulanate absorption and help reduce gastrointestinal intolerance. Tablets should be swallowed with water, and patients should follow the prescribed dosing schedule. Antibiotics should not be shared with others or used for illnesses that have not been medically assessed.
Usage During Pregnancy: AMOXICV may be used during pregnancy when treatment is clinically indicated and a healthcare professional determines that the expected benefits outweigh potential risks. Available evidence is generally reassuring regarding amoxicillin and clavulanate, but treatment should be individualized according to the infection, pregnancy circumstances, and available alternatives. Pregnant patients should consult their healthcare professional before using this medication.
Usage During Breastfeeding: Amoxicillin and clavulanate may pass into breast milk in small amounts. Use during breastfeeding should be discussed with a healthcare professional. The infant should be monitored for possible diarrhea, rash, or other signs of intolerance.
Drug Interactions: AMOXICV may interact with certain medicines, including warfarin and other anticoagulants, methotrexate, probenecid, and allopurinol. These interactions may affect drug exposure, bleeding risk, or the likelihood of adverse reactions. Patients should inform their healthcare professional about all prescription medicines, non-prescription products, and supplements they use before starting treatment.
Clinical Use and Responsible Antibiotic Therapy: AMOXICV should be prescribed for bacterial infections that are proven or strongly suspected to be caused by susceptible organisms. Appropriate antibiotic selection, adherence to the prescribed regimen, and consideration of local antimicrobial resistance patterns are important for effective treatment and responsible antibiotic use.
Product Highlights: AMOXICV 625 mg combines amoxicillin 500 mg with clavulanate potassium 125 mg in a convenient oral tablet. Its complementary antibacterial action, established clinical use, and practical oral administration make it a useful option for healthcare professionals managing selected susceptible bacterial infections.
Product Summary: AMOXICV 625 mg Tablets provide a combination of amoxicillin and clavulanate for the treatment of selected susceptible bacterial infections. Treatment should be guided by a qualified healthcare professional and the locally approved prescribing information.
Medical Notice: This product description is intended for informational and professional website use. Approved indications, dosage recommendations, pregnancy information, and product claims should be verified against the locally registered product information and applicable regulatory requirements before publication.
Company: INTERMED